Abstract MP66: Sex Differences in the Association of Baseline and Longitudinal Changes in Cardiac Biomarkers with Risk of Heart Failure subtypes – a post-hoc analysis of the Look AHEAD trial

Z Zainali Chunawala (University of Texas Southwestern, Dallas, Texas, United States) L Lajjaben Patel (UT Southwestern Medical Center, Dallas, Texas, United States) N Neil Keshvani (UT Southwestern Medical Center, Dallas, Texas, United States) M Matthew Segar (Texas Heart Institute, Houston, Texas, United States) M Mark Espeland (Wake Forest School of Medicine, Winston-Salem, North Carolina, United States) C Christie Ballantyne (BAYLOR COLLEGE MEDICINE, Houston, Texas, United States) J James Januzzi (Baim Institute for Clinical Research, Boston, Massachusetts, United States) C Carolyn Lam (National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore) A Alain Bertoni K Katelyn Garcia (Wake Forest Baptist Health, Winston-Salem, North Carolina, United States) T Thomas Wang (UT Southwestern Medical Center, Dallas, Texas, United States) A Antoni Bayés-Genís A Ambarish Pandey

Abstract

Background: Elevated levels of biomarkers of neurohormonal stress (NT-proBNP) and myocardial injury (hs-TnT) are associated with an increased risk of heart failure (HF) in diabetes. While sex differences in these biomarker profiles and the HF epidemiology are well-established, it is unclear if the prognostic association of biomarkers with the risk of HF differs by sex. Methods: The study included participants of the LookAHEAD trial with overweight/obesity and T2DM. NT-proBNP and hs-TnT were measured at baseline, 1- and 4-year follow-up. HFpEF (LV EF> 50%) and HFrEF (LV EF <50) incidence were adjudicated based on HF hospitalization reports using a well-established protocol. Separate adjusted Cox models were constructed to assess the associations of baseline and longitudinal biomarker changes with the risk of HF subtypes, including sex*biomarker interaction terms. Results: The study included 3959 participants (age: 59 years, 59.3% women, BMI=36 kg/m 2 ) with 108 HFpEF (men vs women: 3.3% vs 2.3%) and 84 HFrEF (men vs women: 2.9% vs 1.6%) events over 12.4 years of follow-up. At baseline, higher NT-proBNP levels were more strongly associated with the risk of HFpEF in females than males (P-int=0.02). In contrast, the association between NT-proBNP and the HFrEF risk was significant and comparable for both sexes ( Table ). The association of elevated hs-TnT levels with the risk of HFpEF did not differ by sex. In contrast, the risk of HFrEF associated with hs-TnT was significantly modified by sex, with a greater risk noted among males (vs. females, Table ). Among those with biomarker assessment on follow-up, an increase in NT-proBNP levels over time was more strongly associated with risk of HFpEF in females than males (P-int=0.01). In contrast, the association between an increase in NT-proBNP levels over time and HFrEF risk did not differ by sex. Repeated measures of hs-TnT over time were not associated with the risk of either HF subtype, with no significant interaction by sex. Conclusion: Among individuals with T2DM with overweight/obesity, the prognostic relevance of cardiac biomarkers for HF outcomes varies by sex. Elevated baseline levels and increase in NT-proBNP over time are more strongly associated with HFpEF risk in females than males. In contrast, elevated hs-TnT is more strongly associated with the risk of HFrEF in males. Further research is needed to determine if sex-specific biomarker screening strategies can inform HF prevention in high-risk individuals.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

Z

Zainali Chunawala

University of Texas Southwestern, Dallas, Texas, United States

L

Lajjaben Patel

UT Southwestern Medical Center, Dallas, Texas, United States

N

Neil Keshvani

UT Southwestern Medical Center, Dallas, Texas, United States

M

Matthew Segar

Texas Heart Institute, Houston, Texas, United States

M

Mark Espeland

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

C

Christie Ballantyne

BAYLOR COLLEGE MEDICINE, Houston, Texas, United States

J

James Januzzi

Baim Institute for Clinical Research, Boston, Massachusetts, United States

C

Carolyn Lam

National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore

A

Alain Bertoni

K

Katelyn Garcia

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

T

Thomas Wang

UT Southwestern Medical Center, Dallas, Texas, United States

A

Antoni Bayés-Genís

A

Ambarish Pandey